Cohance Lifesciences Ltd

Cohance, a company involved in drug product development and manufacturing, has announced a series of strategic acquisitions to strengthen its position in the antibody-drug conjugate (ADC) space. These include acquiring an additional 244,587 shares of its subsidiary, NJ Bio, Inc., for USD 12,963,111, increasing Cohance's ownership to 67.3%, and investing approximately USD 5 million in Aruka Bio, Inc., a company focused on novel ADC platforms, which will result in Cohance (or a subsidiary) holding approximately 65% of Aruka Bio. These transactions, considered related party transactions, are expected to be completed by the end of September 2026, subject to customary closing conditions and regulatory approvals, and are intended to enhance Cohance's capabilities and partnerships within the growing ADC market. NJ Bio, incorporated in 2017 and based in the USA, has seen increasing revenue over the past three years, while Aruka Bio, incorporated in 2023, is currently operating with zero revenue.

Cohance Lifesciences Ltd announced credit rating actions from multiple agencies, including a withdrawal notification from an unspecified agency regarding previously assigned ratings, and a related action from CRISIL Ratings Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; India Ratings and Research Private Limited affirmed its IND3+ rating on Rs 500 crore of Bank Loan Facilities with a Stable outlook, and its IND2 rating on Rs 200 crore of Non-Convertible Debentures, noting that the rating reflects; CARE Ratings upgraded the rating on the Rs 300 crore Term Loan from CARE A- to CARE A; India Ratings continues to maintain credit ratings on higher-limit credit facilities, while CRISIL has withdrawn its CRISIL A1+ rating on the Rs 100 crore Commercial Paper program upon maturity, and withdrawn the Lower Limit Facilities rating as per a letter dated 12 August 2026, stating that the facilities are adequately covered.

Cohance Lifesciences Ltd share price inched up 0.05% to Rs 425.2. The Company's net profit witnessed a sharp fall of 643.80% to Rs 45.19 crore, while revenue from operations dropped sharply 31.80% to Rs 422.26 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 4.98%. It has improved by 0.66% over last one week and advanced by 11.72% in last one month while the market capitalization of Cohance Lifesciences Ltd has softened by 0.58% and 11.54% in the same period respectively. Profit before tax (PBT) of Cohance Lifesciences Ltd stood at Rs 42.87 crore in Q2 FY26, plunging by 168.31% year-on-year, and nosediving by 315.32% quarter-on-quarter. EBITDA came in at Rs 11 crore, tanking 111.33% YoY and tumbling by 111.03% sequentially. Total expenses dropped by 17.67% to Rs 470.64 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 158.68 crore, advancing by 14.19% YoY, while employee benefits expense was at Rs 132.96 crore, ticking higher by 3.08% YoY. For the TTM ended FY26, revenue from operations surged 148.11% to Rs 2608.5 crore, while net profit surged by 61.26% to Rs 484.24 crore, compared to previous TTM. EBITDA jumped by 45510% to Rs 727.85 crore, and PBT witnessed a strong rise of 58.41% to Rs 642.63 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 673.35 crore in FY26, as against Rs 384.77 crore in FY25. Cohance Lifesciences Ltd nosedived by 55.63% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Piramal Pharma Ltd, Kirloskar Oil Engines Ltd, Vedanta Ltd, Neuland Laboratories Ltd are among the other stocks to see a surge in volumes on NSE today, 23 June 2026.Cohance Lifesciences Ltd registered volume of 234.51 lakh shares by 14:14 IST on NSE, a 41.19 fold spurt over two-week average daily volume of 5.69 lakh shares. The stock rose 13.55% to Rs.460.15. Volumes stood at 3.61 lakh shares in the last session.Piramal Pharma Ltd saw volume of 811.88 lakh shares by 14:14 IST on NSE, a 25.97 fold spurt over two-week average daily volume of 31.26 lakh shares. The stock increased 6.43% to Rs.168.70. Volumes stood at 27.1 lakh shares in the last session.Kirloskar Oil Engines Ltd saw volume of 112.23 lakh shares by 14:14 IST on NSE, a 24.16 fold spurt over two-week average daily volume of 4.64 lakh shares. The stock increased 3.75% to Rs.2,479.30. Volumes stood at 17.94 lakh shares in the last session.Vedanta Ltd saw volume of 1586.3 lakh shares by 14:14 IST on NSE, a 8.78 fold spurt over two-week average daily volume of 180.69 lakh shares. The stock dropped 8.34% to Rs.280.35. Volumes stood at 135.51 lakh shares in the last session.Neuland Laboratories Ltd recorded volume of 1.69 lakh shares by 14:14 IST on NSE, a 5.6 times surge over two-week average daily volume of 30124 shares. The stock gained 5.25% to Rs.18,128.00. Volumes stood at 16943 shares in the last session.Powered by Capital Market - Live

Piramal Pharma Ltd, Jain Irrigation Systems Ltd, Aarti Pharmalabs Ltd and BASF India Ltd are among the other gainers in the BSE's 'A' group today, 23 June 2026.Cohance Lifesciences Ltd soared 14.81% to Rs 466.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 12.57 lakh shares were traded on the counter so far as against the average daily volumes of 64696 shares in the past one month. Piramal Pharma Ltd spiked 8.26% to Rs 171.75. The stock was the second biggest gainer in 'A' group. On the BSE, 24.21 lakh shares were traded on the counter so far as against the average daily volumes of 3.48 lakh shares in the past one month. Jain Irrigation Systems Ltd surged 6.44% to Rs 37.5. The stock was the third biggest gainer in 'A' group. On the BSE, 7.85 lakh shares were traded on the counter so far as against the average daily volumes of 2.62 lakh shares in the past one month. Aarti Pharmalabs Ltd exploded 6.02% to Rs 718.1. The stock was the fourth biggest gainer in 'A' group. On the BSE, 60419 shares were traded on the counter so far as against the average daily volumes of 12632 shares in the past one month. BASF India Ltd added 5.81% to Rs 3780.4. The stock was the fifth biggest gainer in 'A' group. On the BSE, 5862 shares were traded on the counter so far as against the average daily volumes of 1636 shares in the past one month. Powered by Capital Market - Live

Kirloskar Oil Engines Ltd, Hero MotoCorp Ltd, Physicswallah Ltd, Prestige Estates Projects Ltd are among the other stocks to see a surge in volumes on BSE today, 23 June 2026.Cohance Lifesciences Ltd recorded volume of 9.61 lakh shares by 10:46 IST on BSE, a 12.91 times surge over two-week average daily volume of 74436 shares. The stock gained 17.17% to Rs.476.00. Volumes stood at 13142 shares in the last session.Kirloskar Oil Engines Ltd clocked volume of 6.55 lakh shares by 10:46 IST on BSE, a 6.69 times surge over two-week average daily volume of 97963 shares. The stock gained 5.61% to Rs.2,525.00. Volumes stood at 3.29 lakh shares in the last session.Hero MotoCorp Ltd registered volume of 72816 shares by 10:46 IST on BSE, a 5 fold spurt over two-week average daily volume of 14575 shares. The stock slipped 0.22% to Rs.4,973.90. Volumes stood at 9178 shares in the last session.Physicswallah Ltd witnessed volume of 37.3 lakh shares by 10:46 IST on BSE, a 4.64 times surge over two-week average daily volume of 8.04 lakh shares. The stock increased 1.82% to Rs.128.40. Volumes stood at 27.35 lakh shares in the last session.Prestige Estates Projects Ltd registered volume of 1.59 lakh shares by 10:46 IST on BSE, a 3.56 fold spurt over two-week average daily volume of 44636 shares. The stock rose 3.58% to Rs.1,566.20. Volumes stood at 1.02 lakh shares in the last session.Powered by Capital Market - Live

According to the company's regulatory filing, Agarwal will be relieved from his duties with effect from the close of business hours on September 13, 2026. Agarwal served as a whole-time director and key managerial personnel (KMP) of the company. The resignation is not linked to any material concerns and has been submitted to enable him to pursue opportunities outside the organisation. The company has not yet announced a successor for the CFO role. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers. The company's consolidated net profit tanked 66.8% to Rs 44.67 crore on 26.2% decline in revenue from operations to Rs 567.55 crore in Q4 FY26 over Q4 FY25. The scrip declined 2.42% to end at Rs 415.55 on the BSE. Powered by Capital Market - Live

Net profit of Cohance Lifesciences declined 83.77% to Rs 19.55 crore in the quarter ended March 2026 as against Rs 120.43 crore during the previous quarter ended March 2025. Sales declined 26.33% to Rs 619.12 crore in the quarter ended March 2026 as against Rs 840.42 crore during the previous quarter ended March 2025. For the full year,net profit declined 63.22% to Rs 179.23 crore in the year ended March 2026 as against Rs 487.34 crore during the previous year ended March 2025. Sales declined 13.03% to Rs 2268.55 crore in the year ended March 2026 as against Rs 2608.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales619.12840.42 -26 2268.552608.50 -13 OPM %15.9427.27 -18.8230.56 - PBDT87.65230.82 -62 423.84825.21 -49 PBT36.42176.65 -79 236.51658.41 -64 NP19.55120.43 -84 179.23487.34 -63 Powered by Capital Market - Live

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 May 2026.